S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

$21.60
+0.62 (+2.96%)
(As of 03/28/2024 ET)
Today's Range
$20.64
$21.81
50-Day Range
$18.89
$26.06
52-Week Range
$3.60
$28.15
Volume
326,854 shs
Average Volume
576,889 shs
Market Capitalization
$778.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50

Longboard Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.9% Upside
$39.50 Price Target
Short Interest
Bearish
11.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.31mentions of Longboard Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$96.48 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.01) to ($2.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.26 out of 5 stars

Medical Sector

369th out of 938 stocks

Pharmaceutical Preparations Industry

168th out of 417 stocks

LBPH stock logo

About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

LBPH Stock Price History

LBPH Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
LBPH Apr 2024 17.500 put
Recap: Longboard Pharmaceuticals Q4 Earnings
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
LBPH May 2024 30.000 call
LBPH Mar 2024 22.500 call
LBPH Aug 2024 15.000 put
Longboard Pharmaceuticals, Inc. (LBPH)
LBPH Feb 2024 30.000 call
TCBP and PCSA among pre-market losers
Behind The Huge Rally In Longboard Pharmaceuticals
See More Headlines
Receive LBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LBPH
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.50
High Stock Price Target
$60.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+82.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-54,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.67 per share

Miscellaneous

Free Float
34,011,000
Market Cap
$777.97 million
Optionable
Optionable
Beta
1.27
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Kevin R. Lind (Age 48)
    President, CEO, Secretary & Director
    Comp: $961.85k
  • Ms. Brandi L. Roberts CPA (Age 50)
    M.B.A., Executive VP & CFO
    Comp: $610.07k
  • Dr. Randall E. Kaye M.D. (Age 62)
    Executive VP & Chief Medical Officer
    Comp: $629.03k
  • Mr. Chadwick J. Orevillo MPH
    Executive VP & Head of Operations
  • Megan E. Knight
    VP & Head of Investor Relations
  • Mr. Steven W. Spector J.D. (Age 59)
    Executive VP, Head of Business Development & General Counsel
  • Dr. Anne M. Danks Ph.D.
    VP & Head of Nonclinical Development
  • Mr. Gus Cardenas
    VP & Head of Quality Assurance
  • Dr. Marco Peters Ph.D.
    VP & Head of Translational Science
  • Dr. Dewey McLin Ph.D.
    VP & Head of Medical Affairs

LBPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Longboard Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LBPH shares.
View LBPH analyst ratings
or view top-rated stocks.

What is Longboard Pharmaceuticals' stock price target for 2024?

6 brokerages have issued twelve-month target prices for Longboard Pharmaceuticals' stock. Their LBPH share price targets range from $13.00 to $60.00. On average, they anticipate the company's stock price to reach $39.50 in the next year. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for LBPH
or view top-rated stocks among Wall Street analysts.

How have LBPH shares performed in 2024?

Longboard Pharmaceuticals' stock was trading at $6.03 at the beginning of 2024. Since then, LBPH stock has increased by 258.2% and is now trading at $21.60.
View the best growth stocks for 2024 here
.

When is Longboard Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LBPH earnings forecast
.

How were Longboard Pharmaceuticals' earnings last quarter?

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) posted its earnings results on Thursday, November, 4th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.10.

When did Longboard Pharmaceuticals IPO?

Longboard Pharmaceuticals (LBPH) raised $75 million in an initial public offering on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor acted as the underwriters for the IPO.

Who are Longboard Pharmaceuticals' major shareholders?

Longboard Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.82%), Price T Rowe Associates Inc. MD (6.82%), Vanguard Group Inc. (3.30%), Vanguard Group Inc. (3.30%), Jennison Associates LLC (2.02%) and Parkman Healthcare Partners LLC (1.80%).
View institutional ownership trends
.

How do I buy shares of Longboard Pharmaceuticals?

Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LBPH) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners